Latvija - latviešu - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 150 μg

Latvija - latviešu - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 100 μg

Latvija - latviešu - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 50 μg

Latvija - latviešu - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 125 μg

Latvija - latviešu - Zāļu valsts aģentūra

berlin-chemie ag (menarini group), germany - levotiroksīna nātrija sāls - tablete - 75 μg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - skābes acetylsalicylicum - zarnās šķīstošā tablete - 75 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - skābes acetylsalicylicum - zarnās šķīstošā tablete - 160 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - skābes acetylsalicylicum - zarnās šķīstošā tablete - 100 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.